TISIDB

Summary
Symbol	ITPKA
Name	inositol-trisphosphate 3-kinase A
Aliases	IP3KA; IP3-3KA; inositol 1,4,5-trisphosphate 3-kinase A; IP3 3-kinase A; IP3K A; insP 3-kinase A
Chromosomal Location	15q15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF03770 Inositol polyphosphate kinase
Function	-

> Gene Ontology [ TOP ]
Biological Process	GO:0006020 inositol metabolic process GO:0006066 alcohol metabolic process GO:0010720 positive regulation of cell development GO:0010769 regulation of cell morphogenesis involved in differentiation GO:0010770 positive regulation of cell morphogenesis involved in differentiation GO:0010975 regulation of neuron projection development GO:0010976 positive regulation of neuron projection development GO:0016358 dendrite development GO:0019751 polyol metabolic process GO:0022604 regulation of cell morphogenesis GO:0031346 positive regulation of cell projection organization GO:0043647 inositol phosphate metabolic process GO:0043954 cellular component maintenance GO:0044262 cellular carbohydrate metabolic process GO:0044723 single-organism carbohydrate metabolic process GO:0045666 positive regulation of neuron differentiation GO:0048167 regulation of synaptic plasticity GO:0048667 cell morphogenesis involved in neuron differentiation GO:0048813 dendrite morphogenesis GO:0048814 regulation of dendrite morphogenesis GO:0050769 positive regulation of neurogenesis GO:0050773 regulation of dendrite development GO:0050775 positive regulation of dendrite morphogenesis GO:0050804 modulation of synaptic transmission GO:0051962 positive regulation of nervous system development GO:0060996 dendritic spine development GO:0060997 dendritic spine morphogenesis GO:0060998 regulation of dendritic spine development GO:0060999 positive regulation of dendritic spine development GO:0061001 regulation of dendritic spine morphogenesis GO:0061003 positive regulation of dendritic spine morphogenesis GO:0097061 dendritic spine organization GO:0097062 dendritic spine maintenance GO:1900006 positive regulation of dendrite development GO:1901615 organic hydroxy compound metabolic process
Molecular Function	GO:0004674 protein serine/threonine kinase activity GO:0004683 calmodulin-dependent protein kinase activity GO:0005516 calmodulin binding GO:0008440 inositol-1,4,5-trisphosphate 3-kinase activity GO:0017016 Ras GTPase binding GO:0017048 Rho GTPase binding GO:0031267 small GTPase binding GO:0048365 Rac GTPase binding GO:0051020 GTPase binding GO:0051766 inositol trisphosphate kinase activity
Cellular Component	GO:0030425 dendrite GO:0043197 dendritic spine GO:0044309 neuron spine GO:0098794 postsynapse

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04020 Calcium signaling pathway hsa04070 Phosphatidylinositol signaling system hsa00562 Inositol phosphate metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-1483249: Inositol phosphate metabolism R-HSA-1430728: Metabolism R-HSA-1855204: Synthesis of IP3 and IP4 in the cytosol

Summary
Symbol	ITPKA
Name	inositol-trisphosphate 3-kinase A
Aliases	IP3KA; IP3-3KA; inositol 1,4,5-trisphosphate 3-kinase A; IP3 3-kinase A; IP3K A; insP 3-kinase A
Chromosomal Location	15q15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ITPKA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	ITPKA
Name	inositol-trisphosphate 3-kinase A
Aliases	IP3KA; IP3-3KA; inositol 1,4,5-trisphosphate 3-kinase A; IP3 3-kinase A; IP3K A; insP 3-kinase A
Chromosomal Location	15q15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ITPKA in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ITPKA
Name	inositol-trisphosphate 3-kinase A
Aliases	IP3KA; IP3-3KA; inositol 1,4,5-trisphosphate 3-kinase A; IP3 3-kinase A; IP3K A; insP 3-kinase A
Chromosomal Location	15q15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ITPKA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.215	0.0367
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.494	0.635
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-1.732	0.0296
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.791	0.255
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.626	0.565
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1	0.417
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.441	0.535
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.262	0.81
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.711	0.551
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.124	0.268
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.072	0.109
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.236	0.251

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ITPKA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	ITPKA
Name	inositol-trisphosphate 3-kinase A
Aliases	IP3KA; IP3-3KA; inositol 1,4,5-trisphosphate 3-kinase A; IP3 3-kinase A; IP3K A; insP 3-kinase A
Chromosomal Location	15q15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITPKA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ITPKA
Name	inositol-trisphosphate 3-kinase A
Aliases	IP3KA; IP3-3KA; inositol 1,4,5-trisphosphate 3-kinase A; IP3 3-kinase A; IP3K A; insP 3-kinase A
Chromosomal Location	15q15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITPKA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITPKA. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ITPKA
Name	inositol-trisphosphate 3-kinase A
Aliases	IP3KA; IP3-3KA; inositol 1,4,5-trisphosphate 3-kinase A; IP3 3-kinase A; IP3K A; insP 3-kinase A
Chromosomal Location	15q15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITPKA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ITPKA
Name	inositol-trisphosphate 3-kinase A
Aliases	IP3KA; IP3-3KA; inositol 1,4,5-trisphosphate 3-kinase A; IP3 3-kinase A; IP3K A; insP 3-kinase A
Chromosomal Location	15q15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ITPKA expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ITPKA
Name	inositol-trisphosphate 3-kinase A
Aliases	IP3KA; IP3-3KA; inositol 1,4,5-trisphosphate 3-kinase A; IP3 3-kinase A; IP3K A; insP 3-kinase A
Chromosomal Location	15q15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ITPKA and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ITPKA
Name	inositol-trisphosphate 3-kinase A
Aliases	IP3KA; IP3-3KA; inositol 1,4,5-trisphosphate 3-kinase A; IP3 3-kinase A; IP3K A; insP 3-kinase A
Chromosomal Location	15q15.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ITPKA collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting ITPKA.

ID	Name	Drug Type	Targets	#Targets
DB01863	Inositol 1,3,4,5-Tetrakisphosphate	Small Molecule	AKT1, BTK, CYTH2, CYTH3, DAPP1, ITPKA, PDPK1, PLEKHA4	8
DB03401	1D-myo-inositol 1,4,5-trisphosphate	Small Molecule	CYTH2, EPN1, ITPKA, ITPR1, PLCD1, RDX, SPTBN1	7
DB04395	Phosphoaminophosphonic Acid-Adenylate Ester	Small Molecule	ACTA1, CCT3, CFTR, CSNK2A1, DAPK1, DTYMK, EPHA2, EPHB2, GALK1, GSK ......	26

Browse ITPKA